Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to announce CLL8 trial results for CLL treatment

Roche to announce CLL8 trial results for CLL treatment

7th December 2009

Roche will unveil the results of a medical trial into its chronic lymphocytic leukaemia (CLL) treatment CLL8 at a forthcoming conference.

The phase III trial was a randomised study examining whether patients with previously untreated CLL live longer when they receive MabThera/Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy, rather than FC alone.

Details of the role MabThera/Rituxan plays in the treatment of CLL will be disclosed, as well as its suitability as a therapy for large B-cell lymphoma and indolent non-Hodgkin’s lymphoma.

According to the firm, the data confirms MabThera/Rituxan as the standard of care in haematological cancers, “with over 1.9 million patient exposures recorded worldwide since MabThera/Rituxan launch in 1997”.

Earlier this month, Roche and Ipsen revealed that a treatment they collaborated on – taspoglutide – yielded a positive outcome during a clinical study.

Taspoglutide went head-to-head in the trial with sitagliptin (Januvia) and a placebo therapy for the management of diabetes.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.